Literature DB >> 29760132

A Multimodal Imaging Approach Enables In Vivo Assessment of Antifungal Treatment in a Mouse Model of Invasive Pulmonary Aspergillosis.

Greetje Vande Velde1,2, Katrien Lagrou3, Jennifer Poelmans4,2, Uwe Himmelreich4,2, Liesbeth Vanherp4,2, Luca Zhai4,2, Amy Hillen4,2, Bryan Holvoet5,2, Sarah Belderbos4,2, Matthias Brock6, Johan Maertens7.   

Abstract

Aspergillus fumigatus causes life-threatening lung infections in immunocompromised patients. Mouse models are extensively used in research to assess the in vivo efficacies of antifungals. In recent years, there has been an increasing interest in the use of noninvasive imaging techniques to evaluate experimental infections. However, single imaging modalities have limitations concerning the type of information they can provide. In this study, magnetic resonance imaging and bioluminescence imaging were combined to obtain longitudinal information on the extent of developing lesions and fungal load in a leukopenic mouse model of invasive pulmonary aspergillosis (IPA). This multimodal imaging approach was used to assess changes occurring within lungs of infected mice receiving voriconazole treatment starting at different time points after infection. The results showed that IPA development depends on the inoculum size used to infect animals and that disease can be successfully prevented or treated by initiating intervention during early stages of infection. Furthermore, we demonstrated that a reduction in fungal load is not necessarily associated with the disappearance of lesions on anatomical lung images, especially when antifungal treatment coincides with immune recovery. In conclusion, multimodal imaging allows an investigation of different aspects of disease progression or recovery by providing complementary information on dynamic processes, which are highly useful for assessing the efficacy of (novel) therapeutic compounds in a time- and labor-efficient manner.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  antifungal therapy; invasive pulmonary aspergillosis; mouse model; multimodal imaging

Mesh:

Substances:

Year:  2018        PMID: 29760132      PMCID: PMC6021662          DOI: 10.1128/AAC.00240-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

2.  A multifunctional, synthetic Gaussia princeps luciferase reporter for live imaging of Candida albicans infections.

Authors:  Brice Enjalbert; Anna Rachini; Govindsamy Vediyappan; Donatella Pietrella; Roberta Spaccapelo; Anna Vecchiarelli; Alistair J P Brown; Christophe d'Enfert
Journal:  Infect Immun       Date:  2009-08-17       Impact factor: 3.441

3.  In vivo imaging of disseminated murine Candida albicans infection reveals unexpected host sites of fungal persistence during antifungal therapy.

Authors:  Ilse D Jacobsen; Anja Lüttich; Oliver Kurzai; Bernhard Hube; Matthias Brock
Journal:  J Antimicrob Chemother       Date:  2014-06-20       Impact factor: 5.790

4.  Monitoring photodynamic therapy of localized infections by bioluminescence imaging of genetically engineered bacteria.

Authors:  Tatiana N Demidova; Faten Gad; Touqir Zahra; Kevin P Francis; Michael R Hamblin
Journal:  J Photochem Photobiol B       Date:  2005-10-03       Impact factor: 6.252

5.  Effect of grapefruit juice on serum voriconazole concentrations in the mouse.

Authors:  A M Sugar; X P Liu
Journal:  Med Mycol       Date:  2000-06       Impact factor: 4.076

Review 6.  Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis.

Authors:  Taylor R T Dagenais; Nancy P Keller
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

7.  Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.

Authors:  Célimène Galiger; Matthias Brock; Grégory Jouvion; Amélie Savers; Marianna Parlato; Oumaïma Ibrahim-Granet
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

8.  Bioluminescent Aspergillus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis.

Authors:  Matthias Brock; Grégory Jouvion; Sabrina Droin-Bergère; Olivier Dussurget; Marie-Anne Nicola; Oumaïma Ibrahim-Granet
Journal:  Appl Environ Microbiol       Date:  2008-09-26       Impact factor: 4.792

9.  In vivo bioluminescence imaging and histopathopathologic analysis reveal distinct roles for resident and recruited immune effector cells in defense against invasive aspergillosis.

Authors:  Oumaïma Ibrahim-Granet; Grégory Jouvion; Tobias M Hohl; Sabrina Droin-Bergère; François Philippart; Oh Yoen Kim; Minou Adib-Conquy; Reto Schwendener; Jean-Marc Cavaillon; Matthias Brock
Journal:  BMC Microbiol       Date:  2010-04-08       Impact factor: 3.605

10.  Expression and in vivo determination of firefly luciferase as gene reporter in Saccharomyces cerevisiae.

Authors:  J M Vieites; F Navarro-García; R Pérez-Díaz; J Pla; C Nombela
Journal:  Yeast       Date:  1994-10       Impact factor: 3.239

View more
  8 in total

Review 1.  Monoclonal Antibodies and Invasive Aspergillosis: Diagnostic and Therapeutic Perspectives.

Authors:  Xihua Lian; Amy Scott-Thomas; John G Lewis; Madhav Bhatia; Sean A MacPherson; Yiming Zeng; Stephen T Chambers
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

2.  The Added Value of Longitudinal Imaging for Preclinical In Vivo Efficacy Testing of Therapeutic Compounds against Cerebral Cryptococcosis.

Authors:  Greetje Vande Velde; Uwe Himmelreich; Liesbeth Vanherp; Jennifer Poelmans; Amy Hillen; Guilhem Janbon; Matthias Brock; Katrien Lagrou
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 3.  Let's shine a light on fungal infections: A noninvasive imaging toolbox.

Authors:  Katrien Van Dyck; Ona Rogiers; Greetje Vande Velde; Patrick Van Dijck
Journal:  PLoS Pathog       Date:  2020-03-05       Impact factor: 6.823

Review 4.  Advances in the In Vivo Molecular Imaging of Invasive Aspergillosis.

Authors:  Matthias Gunzer; Christopher R Thornton; Nicolas Beziere
Journal:  J Fungi (Basel)       Date:  2020-12-04

5.  Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model.

Authors:  Laura Seldeslachts; Lore Vanderbeke; Astrid Fremau; Agustin Reséndiz-Sharpe; Cato Jacobs; Bo Laeveren; Tessa Ostyn; Lieve Naesens; Matthias Brock; Frank L Van De Veerdonk; Stephanie Humblet-Baron; Erik Verbeken; Katrien Lagrou; Joost Wauters; Greetje Vande Velde
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

6.  Longitudinal In Vivo Assessment of Host-Microbe Interactions in a Murine Model of Pulmonary Aspergillosis.

Authors:  Shweta Saini; Jennifer Poelmans; Hannelie Korf; James L Dooley; Sayuan Liang; Bella B Manshian; Rein Verbeke; Stefaan J Soenen; Greetje Vande Velde; Ine Lentacker; Katrien Lagrou; Adrian Liston; Conny Gysemans; Stefaan C De Smedt; Uwe Himmelreich
Journal:  iScience       Date:  2019-09-18

Review 7.  Novel Insights into Aspergillus fumigatus Pathogenesis and Host Response from State-of-the-Art Imaging of Host-Pathogen Interactions during Infection.

Authors:  Sébastien C Ortiz; Katie Pennington; Darren D Thomson; Margherita Bertuzzi
Journal:  J Fungi (Basel)       Date:  2022-03-04

8.  Development and multimodal characterization of an elastase-induced emphysema mouse disease model for the COPD frequent bacterial exacerbator phenotype.

Authors:  Irene Rodríguez-Arce; Xabier Morales; Mikel Ariz; Begoña Euba; Nahikari López-López; Maider Esparza; Derek W Hood; José Leiva; Carlos Ortíz-de-Solórzano; Junkal Garmendia
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.